Nothing Special   »   [go: up one dir, main page]

MX2016014355A - Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado. - Google Patents

Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado.

Info

Publication number
MX2016014355A
MX2016014355A MX2016014355A MX2016014355A MX2016014355A MX 2016014355 A MX2016014355 A MX 2016014355A MX 2016014355 A MX2016014355 A MX 2016014355A MX 2016014355 A MX2016014355 A MX 2016014355A MX 2016014355 A MX2016014355 A MX 2016014355A
Authority
MX
Mexico
Prior art keywords
full length
positions
numbering according
antibodies
length antibody
Prior art date
Application number
MX2016014355A
Other languages
English (en)
Inventor
Kettenberger Hubert
Schlothauer Tilman
Foged Jensen Pernille
Koenig Maximiliane
Rand Kasper
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016014355A publication Critical patent/MX2016014355A/es

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D31/00—Other cooling or freezing apparatus
    • F25D31/002—Liquid coolers, e.g. beverage cooler
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D2600/00—Control issues
    • F25D2600/04—Controlling heat transfer
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D2700/00—Means for sensing or measuring; Sensors therefor
    • F25D2700/16—Sensors measuring the temperature of products

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Combustion & Propulsion (AREA)
  • Physics & Mathematics (AREA)
  • Mechanical Engineering (AREA)
  • Thermal Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Devices That Are Associated With Refrigeration Equipment (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un método para seleccionar un anticuerpo de longitud completa que comprende las etapas de a) generar de un anticuerpo de longitud completa precursor una pluralidad de anticuerpos de longitud completa aleatorizando uno o más residuos de aminoácido seleccionados a partir de los residuos de aminoácido en las posiciones 1-23 en el dominio variable de cadena pesada (numeración de conformidad con Kabat), en las posiciones 55-83 en el dominio variable de cadena ligera (numeración de conformidad con Kabat), en las posiciones 145-174 en el primer dominio constante de cadena pesada (numeración de conformidad con el índice EU) y en las posiciones 180- 97 en el primer dominio constante de cadena pesada (numeración de conformidad con el índice EU), b) determinar la intensidad de unión de cada uno de los anticuerpos de longitud completa a partir de la pluralidad de anticuerpos al receptor Fc neonatal humano (FcRn), y c) seleccionar un anticuerpo de longitud completa a partir de la pluralidad de anticuerpos de longitud completa que tiene una diferente intensidad de unión al FcRn que el anticuerpo de longitud completa precursor.
MX2016014355A 2014-06-12 2015-06-10 Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado. MX2016014355A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14172180 2014-06-12
PCT/EP2015/062899 WO2015189249A1 (en) 2014-06-12 2015-06-10 Method for selecting antibodies with modified fcrn interaction

Publications (1)

Publication Number Publication Date
MX2016014355A true MX2016014355A (es) 2017-01-27

Family

ID=50933041

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014355A MX2016014355A (es) 2014-06-12 2015-06-10 Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado.

Country Status (10)

Country Link
US (2) US20170211876A1 (es)
EP (1) EP3155013B1 (es)
JP (2) JP6675329B2 (es)
KR (1) KR20170015920A (es)
CN (1) CN106459191B (es)
BR (1) BR112016025393A2 (es)
CA (1) CA2946430A1 (es)
MX (1) MX2016014355A (es)
RU (1) RU2714153C2 (es)
WO (1) WO2015189249A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017325654B2 (en) 2016-08-02 2024-09-05 Visterra, Inc. Engineered polypeptides and uses thereof
EP3697441B1 (en) * 2017-10-20 2023-06-07 F. Hoffmann-La Roche AG Method for generating multispecific antibodies from monospecific antibodies
CN112955240B (zh) * 2018-10-25 2022-09-16 豪夫迈·罗氏有限公司 抗体FcRn结合的修饰
CA3148764A1 (en) * 2019-07-25 2021-01-28 Genzyme Corporation Methods of treating antibody-mediated disorders with fcrn antagonists
EP4045536A4 (en) * 2019-10-16 2023-11-01 Lg Chem, Ltd. NEONATAL FC RECEPTOR BINDING AFFIMERS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2649037T3 (es) * 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
RU2337107C2 (ru) * 2003-05-02 2008-10-27 Ксенкор, Инк. ОПТИМИЗИРОВАННЫЕ Fc-ВАРИАНТЫ, ИМЕЮЩИЕ ИЗМЕНЕННОЕ СВЯЗЫВАНИЕ С FcγR, И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
CN101098890B (zh) * 2004-11-12 2012-07-18 赞科股份有限公司 对FcRn的结合被改变的Fc变体
EP2164873B2 (en) * 2007-05-31 2018-09-12 Genmab A/S Stable igg4 antibodies
CA2697922A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
WO2010017595A1 (en) * 2008-08-14 2010-02-18 Arana Therapeutics Limited Variant domain antibodies
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
TWI667346B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
WO2012016227A2 (en) * 2010-07-29 2012-02-02 Xencor, Inc. Antibodies with modified isoelectric points
CA3182462A1 (en) * 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
JP6321633B2 (ja) * 2012-06-04 2018-05-09 ノバルティス アーゲー 部位特異的標識法およびそれによって生成される分子
HUE063778T2 (hu) * 2015-01-30 2024-01-28 Momenta Pharmaceuticals Inc FcRn ellenanyagok és eljárások alkalmazásukra
WO2022175217A1 (en) * 2021-02-18 2022-08-25 F. Hoffmann-La Roche Ag Method for resolving complex, multistep antibody interactions

Also Published As

Publication number Publication date
WO2015189249A1 (en) 2015-12-17
JP2020114217A (ja) 2020-07-30
RU2016150952A3 (es) 2019-02-07
RU2714153C2 (ru) 2020-02-12
JP2017525335A (ja) 2017-09-07
CA2946430A1 (en) 2015-12-17
US20210041163A1 (en) 2021-02-11
EP3155013B1 (en) 2019-03-27
JP6675329B2 (ja) 2020-04-01
BR112016025393A2 (pt) 2017-12-12
CN106459191A (zh) 2017-02-22
US20170211876A1 (en) 2017-07-27
KR20170015920A (ko) 2017-02-10
CN106459191B (zh) 2021-12-10
JP7050838B2 (ja) 2022-04-08
EP3155013A1 (en) 2017-04-19
RU2016150952A (ru) 2018-07-12

Similar Documents

Publication Publication Date Title
CY1124993T1 (el) Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20
JOP20200213A1 (ar) جزيئات رابطة لـ pd-1 وطرق استخدامها
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
MX2021012307A (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso.
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
CR20160090A (es) DIACUERPOS MONOVALENTES BIESPECÍFICOS QUE PUEDEN UNIRSE A gpA33 Y CD3, Y SUS USOS
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
CL2017000711A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos.
SG10201901057UA (en) Anti-pd-l1 antibodies
MX2019005426A (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
MY187967A (en) Lag-3-binding molecules and methods of use thereof
MX353278B (es) Raton con cadena ligera comun.
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
PH12016501366A1 (en) Novel anti-baff antibodies
EA201890443A1 (ru) Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение
EA201791270A1 (ru) Модифицированные april-связывающие антитела
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
MX2016014355A (es) Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado.
EA201892063A1 (ru) МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MY188871A (en) Pd-1-binding molecules and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration